Sunitinib, an oral tyrosine kinase inhibitor, targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) and is commonly used as primary therapy for late-stage RCC (18). Here, KDR is linked to renal cell carcinoma.